Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
North America Gastric Cancer Drugs Market Analysis
Gastric cancer is reported to be one of the most life-threatening diseases due to the absence of effective medications and delayed diagnosis. The commonly used treatments include chemotherapy, radiation therapy, and targeted therapy. The stage of gastric cancer and the presence of specific biomarkers usually determine the treatment plan. Recent years have witnessed pivotal progress in the development of novel therapies which is likely to shape the global gastric cancer drugs market dynamics. Medications such as imatinib, regorafenib, entrectinib, and Larotrectinib are increasingly used to treat advanced gastric cancer. Moreover, the surge in clinical trial activities stimulated by substantial fundings in oncology research is poised to propel the North America gastric cancer drugs market growth.
Gastric cancer is a significant health challenge in North America. In 2023, stomach cancer was estimated to cause around 11,130 deaths in the United States. Metastatic gastric cancer is reported to have the lowest 5-year survival rate at 7%. The most frequently diagnosed demographic is individuals between the ages of 65 to 74 years, indicating the need for early detection and successful therapies. Thus, the rising incidence of gastric cancer risk factors (such as aging and sedentary lifestyles) coupled with the increased patient awareness and screening of the disease is projected to fuel the North America gastric cancer drugs market demand in the forecast period.
One of the major market trends is the increased approval of potent gastric cancer drugs by health regulatory bodies. In November 2023 , Merck & Co., Inc.’s immune checkpoint inhibitor pembrolizumab (Keytruda) with fluoropyrimidine- and platinum-containing chemotherapy received United States Food and Drug Administration (FDA) approval for the first-line treatment for gastric or gastroesophageal junction (GEJ) adenocarcinoma in adult patients. The phase 3 KEYNOTE-859 trial of the drug candidate revealed that administration of pembrolizumab before chemotherapy in HER2-negative advanced gastric or GEJ adenocarcinoma patients resulted in significant improvement in overall survival and progression-free survival (PFS), which prompted the FDA approval. The introduction of such innovative drugs to treat gastric cancer is anticipated to elevate the market value in the coming years.
North America Gastric Cancer Drugs Market Report Snapshots
North America Gastric Cancer Drugs Market Size
North America Gastric Cancer Drugs Market Analysis
North America Gastric Cancer Drugs Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 17.10% during the forecast period of 2024-2032, driven by increasing emphasis on oncology research in the region.
The rising incidence of gastric cancer risk factors and heightened patient awareness are fuelling the demand for the market.
One of the significant trends in the market is surge in approvals for novel gastric cancer drugs by health regulatory bodies. In November 2023 , Merck & Co., Inc.’s immune checkpoint inhibitor pembrolizumab (Keytruda) with chemotherapy received FDA approval to treat gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Based on the therapy type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery, among others.
By disease type, the market is divided into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, and carcinoid tumor, among others.
By drug class, the market is divided into PD-1/PD-L1 inhibitors, HER2 antagonists, and VEGFR2 antagonists, among others.
The market breakup by route of administration includes oral and injectable.
Market breakup by end-use includes ambulatory surgery centers, hospitals, and specialty clinics, among others.
Major distribution channels of the market include hospital pharmacies, specialty, and retail pharmacies, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Novartis AG, Pfizer, Inc., Viatris, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124